Inactive Instrument

Small Pharma Inc.

Equities

DMT

CA8316641072

Biotechnology & Medical Research

Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.

January 25, 2023 at 12:02 pm

From September 1, 2022 to November 30, 2022, the company has repurchased 940,000 shares, representing 0.29% for CAD 0.24 million. With this, the company has completed the repurchase of 1,788,000 shares, representing 0.55% for CAD 0.48 million under the buyback announced on August 18, 2022.

Latest news about Small Pharma Inc.

Small Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	01-29	CI
Small Pharma Brief: Cybin Completed Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics	23/10/23	MT
Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).	22/10/23	CI
Small Pharma Brief: Shareholders overwhelmingly voted in favour of Cybin's acquisition	19/10/23	MT
Small Pharma Brief: Q2 FY24 Highlights Include Cash on hand as of August 31, 2023 of approximately C$7.7 million	19/10/23	MT
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	19/10/23	CI
Small Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	19/10/23	CI
Small Pharma Notes Positive Top-line Data from SPL026-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	26/09/23	MT
Small Pharma Brief: Reporting "Positive" Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	26/09/23	MT
Small Pharma Inc. Reports Positive Top-line Data from SPL026 (DMT-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	26/09/23	CI
Cybin Agrees to Acquire Small Pharma in All-Share Deal	28/08/23	MT
Transcript : Small Pharma Inc., Cybin Inc. - M&A Call	28/08/23
Small Pharma Inc.'s Equity Buyback announced on August 18, 2022, has expired with 1,788,000 shares, representing 0.55% for CAD 0.48 million.	17/08/23	CI
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	26/07/23	CI
Small Pharma Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023	26/07/23	CI
Small Pharma Announces SPL028 R&D Strategy Update; Separately Announced Management Team Change	05/07/23	MT
Small Pharma Inc. Announces Management Changes	05/07/23	CI
Small Pharma Announces SPL028 R&D Strategy Update	05/07/23	CI
Small Pharma Inc. Announces Executive Team Change	05/07/23	CI
Small Pharma Brief: Notes "Operational Efficiencies Underway To Deliver Meaningful Runway Extension"	28/06/23	MT
Small Pharma Brief: For FY23, Adds Preliminary findings from SPL028 Phase I clinical trial support target drug profile	28/06/23	MT
Small Pharma Brief: For FY23, Says Multiple clinical milestones achieved including Frst proof-of-concept for DMT-based therapies from a blinded placebo-controlled study	28/06/23	MT
Small Pharma Brief: Says Cash on hand as of February 28, 2023 was approximately $18.5 million	28/06/23	MT
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	28/06/23	CI
Small Pharma Inc. Reports Earnings Results for the Full Year Ended February 28, 2023	28/06/23	CI

Chart Small Pharma Inc.

Duration

Period

More charts

Company Profile

Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of depression. It has a portfolio of clinical-stage dimethyltryptamine (DMT)-based assets, SPL026 and SPL028. It has a pipeline of proprietary preclinical assets. Its clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a Phase IIa study, IV SPL026 demonstrated a rapid and durable antidepressant effect, as well as a favorable safety and tolerability profile. Small Pharma is also advancing SPL028, a second-generation injectable deuterated DMT molecule, in a Phase I trial.

Sector

Biotechnology & Medical Research

Calendar

25/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research